Analysis of the clinical efficacy of avatrombopag (Su Kexin) in the treatment of thrombocytopenia

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA). It mainly promotes bone marrow megakaryocyte proliferation and platelet production by activating TPO receptors, thereby improving thrombocytopenia symptoms. The drug is indicated for patients with thrombocytopenia associated with chronic liver disease (especially before invasive procedures) and adults with immune thrombocytopenia (ITP). As an oral formulation, avatrombopag avoids the inconvenience of injections and improves patient compliance.

Clinical studies have shown that avatrombopag can significantly increase the platelet count in patients with chronic liver disease, providing safe operating conditions for liver puncture, endoscopic treatment or surgery. In pivotal trials, most patients achieved acceptable surgical thresholds (usually ≥50 × 10^9/L) within 5 to 10 days of starting the drug, eliminating the need for platelet transfusions. This not only reduces transfusion dependence but also reduces the risks associated with platelet preparations, such as allergic reactions or viral transmission.

Avatrombopag also showed good efficacy inITP patients. Studies have shown that long-term oral treatment can maintain platelets at safe levels (≥50×10^9/L) and reduce the incidence of bleeding events. Some research reports show that about 65%-70% of patients achieve platelet response after several weeks of continuous treatment and can maintain it stable for several months. This provides a safe, effective and long-term sustainable oral treatment option for ITP patients.

Avatrombopag is generally well tolerated, and common adverse reactions include headache, fatigue, and mild thrombotic events. Patients need to regularly monitor their platelet count while taking the drug so that the dose can be adjusted in a timely manner. It is clinically recommended to be used under the guidance of a doctor, especially in patients with low platelet counts or high risk of blood clots. Overall, avatrombopag provides a reliable treatment option for patients with thrombocytopenia due to its rapid platelet elevation, oral convenience, and good tolerability.

Reference materials:https://www.drugs.com/